AbbVie Inc. $ABBV Shares Bought by International Private Wealth Advisors LLC

International Private Wealth Advisors LLC lifted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 79.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,784 shares of the company’s stock after purchasing an additional 2,998 shares during the quarter. AbbVie comprises about 1.0% of International Private Wealth Advisors LLC’s investment portfolio, making the stock its 27th largest holding. International Private Wealth Advisors LLC’s holdings in AbbVie were worth $1,571,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie in the second quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in AbbVie in the 2nd quarter valued at about $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie during the 2nd quarter valued at about $39,000. Finally, Abich Financial Wealth Management LLC bought a new position in shares of AbbVie during the 3rd quarter valued at about $49,000. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

Analyst Ratings Changes

A number of analysts recently commented on ABBV shares. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a report on Thursday, January 15th. Scotiabank started coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective for the company. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 27th. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. Finally, Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Trading Up 1.8%

Shares of ABBV stock opened at $231.57 on Friday. The company has a market capitalization of $409.28 billion, a price-to-earnings ratio of 98.12, a P/E/G ratio of 0.79 and a beta of 0.35. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock’s fifty day simple moving average is $223.56 and its 200-day simple moving average is $220.64.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the company posted $2.16 EPS. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.